+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Rectal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • PDF Icon

    Report

  • 131 Pages
  • April 2022
  • Region: Global
  • Global Markets Direct
  • ID: 5589921
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The latest Pharmaceutical and Healthcare disease pipeline guide Rectal Cancer - Drugs In Development, 2022, provides an overview of the Rectal Cancer (Oncology) pipeline landscape.

Rectal cancer affects the lower part of the colon, which connects the large bowel to the anus. The risk factors for developing rectal cancer are increasing age, smoking, family history of colon or rectal cancer, high-fat diet and/or a diet mostly from animal sources and personal or family history of polyps or colorectal cancer. Rectal cancer commonly spreads to organs such as the liver and the lungs. The common signs and symptoms of rectal cancer include a change in bowel habits, diarrhea, constipation, or feeling that the bowel does not empty completely, blood, either bright red or very dark in the stool, stools that are narrower than usual, general abdominal discomfort such as frequent gas pains, bloating, fullness or cramps, weight loss with no known reason, constant tiredness and vomiting. Rectal cancer treatment includes surgery, radiation therapy or chemotherapy, or a combination of these approaches

Report Highlights


The Pharmaceutical and Healthcare latest pipeline guide Rectal Cancer - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Rectal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rectal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Rectal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 19, 25, 5 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Rectal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Rectal Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Rectal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Rectal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Rectal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Rectal Cancer (Oncology)

Reasons to Buy


  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Rectal Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Rectal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

IntroductionReport CoverageRectal Cancer - Overview
Rectal Cancer - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
Rectal Cancer - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Rectal Cancer - Companies Involved in Therapeutics DevelopmentRectal Cancer - Drug ProfilesRectal Cancer - Dormant ProjectsRectal Cancer - Discontinued ProductsRectal Cancer - Product Development Milestones
Featured News & Press Releases
  • Nov 12, 2021: Apexigen announces new phase 2 clinical data on CD40 antibody sotigalimab at the SITC 2021 Annual Meeting
  • Feb 04, 2021: National Comprehensive Cancer Network provides updates on use of LONSURF (trifluridine and tipiracil) in NCCN Drugs and Biologics Compendium for colon cancer and rectal cancer
  • Oct 22, 2018: NCCN awarded $2 million in research funding from Taiho Oncology to study Trifluridine and Tipiracil in various cancers
AppendixMethodologyCoverageSecondary ResearchPrimary ResearchExpert Panel ValidationContact the Analyst
List of Tables
  • Number of Products under Development for Rectal Cancer, 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products under Development by Universities/Institutes, 2022
  • Products under Development by Companies, 2022
  • Products under Development by Universities/Institutes, 2022
  • Number of Products by Stage and Target, 2022
  • Number of Products by Stage and Mechanism of Action, 2022
  • Number of Products by Stage and Route of Administration, 2022
  • Number of Products by Stage and Molecule Type, 2022
  • Rectal Cancer - Pipeline by Advaxis Inc, 2022
  • Rectal Cancer - Pipeline by Alkermes Plc, 2022
  • Rectal Cancer - Pipeline by Amphivena Therapeutics Inc, 2022
  • Rectal Cancer - Pipeline by Apexigen Inc, 2022
  • Rectal Cancer - Pipeline by AptaBio Therapeutics Inc, 2022
  • Rectal Cancer - Pipeline by Arcus Biosciences Inc, 2022
  • Rectal Cancer - Pipeline by AstraZeneca Plc, 2022
  • Rectal Cancer - Pipeline by BeiGene Ltd, 2022
  • Rectal Cancer - Pipeline by Beijing Konruns Pharmaceutical Co Ltd, 2022
  • Rectal Cancer - Pipeline by BioAtla Inc, 2022
  • Rectal Cancer - Pipeline by Biomimetix JV LLC, 2022
  • Rectal Cancer - Pipeline by Bristol-Myers Squibb Co, 2022
  • Rectal Cancer - Pipeline by CytomX Therapeutics Inc, 2022
  • Rectal Cancer - Pipeline by Diverse Biotech Inc, 2022
  • Rectal Cancer - Pipeline by Eisai Co Ltd, 2022
  • Rectal Cancer - Pipeline by Eli Lilly and Co, 2022
  • Rectal Cancer - Pipeline by Ellipses Pharma Ltd, 2022
  • Rectal Cancer - Pipeline by F. Hoffmann-La Roche Ltd, 2022
  • Rectal Cancer - Pipeline by Genentech USA Inc, 2022
  • Rectal Cancer - Pipeline by Genexine Inc, 2022
  • Rectal Cancer - Pipeline by Genome & Co, 2022
  • Rectal Cancer - Pipeline by GlaxoSmithKline Plc, 2022
  • Rectal Cancer - Pipeline by Harbin Gloria Pharmaceuticals Co Ltd, 2022
  • Rectal Cancer - Pipeline by Hutchison MediPharma Ltd, 2022
  • Rectal Cancer - Pipeline by Incyte Corp, 2022
  • Rectal Cancer - Pipeline by Innovent Biologics Inc, 2022
  • Rectal Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
  • Rectal Cancer - Pipeline by LipoMedix Pharmaceutical Inc, 2022
  • Rectal Cancer - Pipeline by Merck & Co Inc, 2022
  • Rectal Cancer - Pipeline by Merck KGaA, 2022
  • Rectal Cancer - Pipeline by Millennium Pharmaceuticals Inc, 2022
  • Rectal Cancer - Pipeline by Novartis AG, 2022
  • Rectal Cancer - Pipeline by Oncolys BioPharma Inc, 2022
  • Rectal Cancer - Pipeline by OncXerna Therapeutics Inc, 2022
  • Rectal Cancer - Pipeline by Ono Pharmaceutical Co Ltd, 2022
  • Rectal Cancer - Pipeline by Pieris Pharmaceuticals Inc, 2022
  • Rectal Cancer - Pipeline by Precigen Inc, 2022
  • Rectal Cancer - Pipeline by Privo Technologies Inc, 2022
  • Rectal Cancer - Pipeline by Sanofi, 2022
  • Rectal Cancer - Pipeline by Shanghai Haihe Biopharma Co Ltd, 2022
  • Rectal Cancer - Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2022
  • Rectal Cancer - Pipeline by SQZ Biotechnologies Co, 2022
  • Rectal Cancer - Pipeline by Taiho Oncology Inc, 2022
  • Rectal Cancer - Pipeline by Teon Therapeutics Inc, 2022
  • Rectal Cancer - Dormant Projects, 2022
  • Rectal Cancer - Discontinued Products, 2022

List of Figures
  • Number of Products under Development for Rectal Cancer, 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products by Top 10 Targets, 2022
  • Number of Products by Stage and Top 10 Targets, 2022
  • Number of Products by Top 10 Mechanism of Actions, 2022
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2022
  • Number of Products by Top 10 Routes of Administration, 2022
  • Number of Products by Stage and Top 10 Routes of Administration, 2022
  • Number of Products by Top 10 Molecule Types, 2022
  • Number of Products by Stage and Top 10 Molecule Types, 2022

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Advaxis Inc
  • Alkermes Plc
  • Amphivena Therapeutics Inc
  • Apexigen Inc
  • AptaBio Therapeutics Inc
  • Arcus Biosciences Inc
  • AstraZeneca Plc
  • BeiGene Ltd
  • Beijing Konruns Pharmaceutical Co Ltd
  • BioAtla Inc
  • Biomimetix JV LLC
  • Bristol-Myers Squibb Co
  • CytomX Therapeutics Inc
  • Diverse Biotech Inc
  • Eisai Co Ltd
  • Eli Lilly and Co
  • Ellipses Pharma Ltd
  • F. Hoffmann-La Roche Ltd
  • Genentech USA Inc
  • Genexine Inc
  • Genome & Co
  • GlaxoSmithKline Plc
  • Harbin Gloria Pharmaceuticals Co Ltd
  • Hutchison MediPharma Ltd
  • Incyte Corp
  • Innovent Biologics Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • LipoMedix Pharmaceutical Inc
  • Merck & Co Inc
  • Merck KGaA
  • Millennium Pharmaceuticals Inc
  • Novartis AG
  • Oncolys BioPharma Inc
  • OncXerna Therapeutics Inc
  • Ono Pharmaceutical Co Ltd
  • Pieris Pharmaceuticals Inc
  • Precigen Inc
  • Privo Technologies Inc
  • Sanofi
  • Shanghai Haihe Biopharma Co Ltd
  • Shenzhen Chipscreen Biosciences Co Ltd
  • SQZ Biotechnologies Co
  • Taiho Oncology Inc
  • Teon Therapeutics Inc